Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.

$Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.$
Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.

Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient.

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.

$Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.$
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.

$Percutaneous urinary diversion in patients with hormone-refractory prostate cancer.$
Percutaneous urinary diversion in patients with hormone-refractory prostate cancer.

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy.

Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice.

Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer.

Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer.

[Metastatic hormone-sensitive prostate cancer].

Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.

Prostate-specific antigen pox virus vaccination for recurrent prostate cancer.

$A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.$
A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.

Integrating circulating tumor cell data with imaging and serum prostate-specific antigen measurement for metastatic prostate cancer therapy management.

$Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.$
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer.

Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.

Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?

$Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.$
Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Suggest Documents

Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.

Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient.

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.

Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.

Percutaneous urinary diversion in patients with hormone-refractory prostate cancer.

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy.

Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice.

Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer.

Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer.

[Metastatic hormone-sensitive prostate cancer].

Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.

Prostate-specific antigen pox virus vaccination for recurrent prostate cancer.

A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer.

Integrating circulating tumor cell data with imaging and serum prostate-specific antigen measurement for metastatic prostate cancer therapy management.

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer.

Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.

Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level.

Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.

Recommend Documents

Follow Us